类风湿性关节炎相关间质性肺疾病的药物治疗新进展
New Advances in the Pharmacological Management of Rheumatoid Arthritis-Related Interstitial Lung Disease
DOI: 10.12677/acm.2025.1541314, PDF,   
作者: 杨 燕：重庆医科大学，重庆；张 劼*：重庆医科大学，重庆；重庆市人民医院老年病科，重庆
关键词: 类风湿性关节炎；间质性肺疾病；抗纤维化药物；免疫抑制剂；Rheumatoid Arthritis； Interstitial Lung Disease； Antifibrotic Drugs； Immunosuppressants
摘要: 类风湿性关节炎(RA)是一种全身性炎症性疾病，RA最常见的关节外表现是肺部受累。间质性肺疾病(ILD)是类风湿性关节炎的常见并发症，发病率和死亡率都很高。目前，国际上对RA-ILD的最佳治疗方法尚未明确。对于RA-ILD患者，目标应该是缓解RA和阻止ILD的进展。因此，了解RA-ILD的治疗方案的最新进展，这对改善患者预后至关重要。RA治疗包括常规合成的改善病情的抗风湿药物(DMARDs)，生物合成DMARDs，以及靶向合成DMARDs，而这些药物也被常规用于对RA-ILD的治疗评估。本篇综述中不仅总结了上述药物用于RA-ILD最新进展，还评价了抗纤维化药物用于治疗RA-ILD的新进展。本文通过对这些药物的最新进展进行总结，为临床指导RA-ILD用药提供参考依据。
Abstract: Rheumatoid arthritis (RA) is a systemic inflammatory disease and the most common extra-articular manifestation of RA is pulmonary involvement. Interstitial lung disease (ILD) is a common complication of rheumatoid arthritis with high morbidity and mortality. Currently, the optimal treatment for RA-ILD is not well defined internationally. For patients with RA-ILD, the goal should be to alleviate RA and halt the progression of ILD. Therefore, it is important to be aware of the latest advances in treatment options for RA-ILD, which are essential for improving patient prognosis. RA treatments include conventional synthetic disease-modifying antirheumatic drugs (DMARDs), biosynthetic DMARDs, and targeted synthetic DMARDs, which are also routinely used for therapeutic evaluation of RA-ILD. In this review, we not only summarise the latest advances in the use of the above drugs for RA-ILD, but also evaluate the new advances in the use of antifibrotic drugs for the treatment of RA-ILD. By summarising the latest advances of these drugs, this article provides a reference basis for clinical guidance on the use of drugs for RA-ILD.
文章引用：杨燕, 张劼. 类风湿性关节炎相关间质性肺疾病的药物治疗新进展[J]. 临床医学进展, 2025, 15(4): 3420-3428. https://doi.org/10.12677/acm.2025.1541314

参考文献

[1] Liang, M., Matteson, E.L., Abril, A. and Distler, J.H.W. (2022) The Role of Antifibrotics in the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Therapeutic Advances in Musculoskeletal Disease, 14. [Google Scholar] [CrossRef] [PubMed]
[2] Safiri, S., Kolahi, A.A., Hoy, D., Smith, E., Bettampadi, D., Mansournia, M.A., et al. (2019) Global, Regional and National Burden of Rheumatoid Arthritis 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017. Annals of the Rheumatic Diseases, 78, 1463-1471. [Google Scholar] [CrossRef] [PubMed]
[3] Turesson, C., O’Fallon, W.M., Crowson, C.S., Gabriel, S.E. and Matteson, E.L. (2003) Extra-Articular Disease Manifestations in Rheumatoid Arthritis: Incidence Trends and Risk Factors over 46 Years. Annals of the Rheumatic Diseases, 62, 722-727. [Google Scholar] [CrossRef] [PubMed]
[4] Suda, T. (2015) Up-to-Date Information on Rheumatoid Arthritis-Associated Interstitial Lung Disease. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 9, CCRPM.S23289. [Google Scholar] [CrossRef] [PubMed]
[5] Farquhar, H., Vassallo, R., Edwards, A.L. and Matteson, E.L. (2019) Pulmonary Complications of Rheumatoid Arthritis. Seminars in Respiratory and Critical Care Medicine, 40, 194-207. [Google Scholar] [CrossRef] [PubMed]
[6] Spagnolo, P., Lee, J.S., Sverzellati, N., Rossi, G. and Cottin, V. (2018) The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis & Rheumatology, 70, 1544-1554. [Google Scholar] [CrossRef] [PubMed]
[7] Koduri, G. and Solomon, J.J. (2023) Identification, Monitoring, and Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthritis & Rheumatology, 75, 2067-2077. [Google Scholar] [CrossRef] [PubMed]
[8] Yamakawa, H., Sato, S., Nishizawa, T., Kawabe, R., Oba, T., Kato, A., et al. (2020) Impact of Radiological Honeycombing in Rheumatoid Arthritis-Associated Interstitial Lung Disease. BMC Pulmonary Medicine, 20, Article No. 25. [Google Scholar] [CrossRef] [PubMed]
[9] Bongartz, T., Nannini, C., Medina‐Velasquez, Y.F., Achenbach, S.J., Crowson, C.S., Ryu, J.H., et al. (2010) Incidence and Mortality of Interstitial Lung Disease in Rheumatoid Arthritis: A Population‐Based Study. Arthritis & Rheumatism, 62, 1583-1591. [Google Scholar] [CrossRef] [PubMed]
[10] Narváez, J., Díaz del Campo Fontecha, P., Brito García, N., Bonilla, G., Aburto, M., Castellví, I., et al. (2022) SER-SEPAR Recommendations for the Management of Rheumatoid Arthritis-Related Interstitial Lung Disease. Part 2: Treatment. Reumatología Clínica (English Edition), 18, 501-512. [Google Scholar] [CrossRef] [PubMed]
[11] Yu, K., Chen, H., Cheng, T., Jan, Y., Weng, M., Lin, Y., et al. (2022) Consensus Recommendations on Managing the Selected Comorbidities Including Cardiovascular Disease, Osteoporosis, and Interstitial Lung Disease in Rheumatoid Arthritis. Medicine, 101, e28501. [Google Scholar] [CrossRef] [PubMed]
[12] Hyldgaard, C., Ellingsen, T., Hilberg, O. and Bendstrup, E. (2019) Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality. Respiration, 98, 455-460. [Google Scholar] [CrossRef] [PubMed]
[13] Zamora-Legoff, J.A., Krause, M.L., Crowson, C.S., Ryu, J.H. and Matteson, E.L. (2016) Patterns of Interstitial Lung Disease and Mortality in Rheumatoid Arthritis. Rheumatology, 56, 344-350. [Google Scholar] [CrossRef] [PubMed]
[14] Brooks, R., Baker, J.F., Yang, Y., Roul, P., Kerr, G.S., Reimold, A.M., et al. (2022) The Impact of Disease Severity Measures on Survival in U.S. Veterans with Rheumatoid Arthritis-Associated Interstitial Lung Disease. Rheumatology, 61, 4667-4677.
[15] Sparks, J.A., Jin, Y., Cho, S., Vine, S., Desai, R., Doyle, T.J., et al. (2021) Prevalence, Incidence and Cause-Specific Mortality of Rheumatoid Arthritis–associated Interstitial Lung Disease among Older Rheumatoid Arthritis Patients. Rheumatology, 60, 3689-3698. [Google Scholar] [CrossRef] [PubMed]
[16] Qiu, M., Jiang, J., Nian, X., Wang, Y., Yu, P., Song, J., et al. (2021) Factors Associated with Mortality in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Respiratory Research, 22, Article No. 264. [Google Scholar] [CrossRef] [PubMed]
[17] Kim, E.J., Elicker, B.M., Maldonado, F., Webb, W.R., Ryu, J.H., Van Uden, J.H., et al. (2009) Usual Interstitial Pneumonia in Rheumatoid Arthritis-Associated Interstitial Lung Disease. European Respiratory Journal, 35, 1322-1328. [Google Scholar] [CrossRef] [PubMed]
[18] Raghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C.C., Inoue, Y., Johkoh, T., et al. (2022) Idiopathic Pulmonary Fibrosis (an Up-date) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 205, e18-e47.
[19] Huang, S., Kronzer, V.L., Dellaripa, P.F., Deane, K.D., Bolster, M.B., Nagaraja, V., et al. (2020) Rheumatoid Arthritis–associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment. Current Treatment Options in Rheumatology, 6, 337-353. [Google Scholar] [CrossRef] [PubMed]
[20] Bendstrup, E., Møller, J., Kronborg-White, S., Prior, T.S. and Hyldgaard, C. (2019) Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians. Journal of Clinical Medicine, 8, Article 2038. [Google Scholar] [CrossRef] [PubMed]
[21] England, B.R. and Hershberger, D. (2020) Management Issues in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Current Opinion in Rheumatology, 32, 255-263. [Google Scholar] [CrossRef] [PubMed]
[22] George, P.M., Spagnolo, P., Kreuter, M., Altinisik, G., Bonifazi, M., Martinez, F.J., et al. (2020) Progressive Fibrosing Interstitial Lung Disease: Clinical Uncertainties, Consensus Recommendations, and Research Priorities. The Lancet Respiratory Medicine, 8, 925-934. [Google Scholar] [CrossRef] [PubMed]
[23] King, T.E., Bradford, W.Z., Castro-Bernardini, S., Fagan, E.A., Glaspole, I., Glassberg, M.K., et al. (2014) A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 370, 2083-2092. [Google Scholar] [CrossRef] [PubMed]
[24] Flaherty, K.R., Wells, A.U., Cottin, V., Devaraj, A., Walsh, S.L.F., Inoue, Y., et al. (2019) Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 381, 1718-1727. [Google Scholar] [CrossRef] [PubMed]
[25] Kadura, S. and Raghu, G. (2021) Rheumatoid Arthritis-Interstitial Lung Disease: Manifestations and Current Concepts in Pathogenesis and Management. European Respiratory Review, 30, Article ID: 210011. [Google Scholar] [CrossRef] [PubMed]
[26] Solomon, J.J., Danoff, S.K., Woodhead, F.A., Hurwitz, S., Maurer, R., Glaspole, I., et al. (2023) Safety, Tolerability, and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Randomised, Double-Blind, Place-Bo-Controlled, Phase 2 Study. The Lancet Respiratory Medicine, 11, 87-96.
[27] Yang, M., Wu, Y., Liu, X., Zhao, C., Li, T., Li, T., et al. (2023) Efficacy and Safety of Antifibrotic Agents in the Treatment of CTD-ILD and RA-ILD: A Systematic Review and Meta-Analysis. Respiratory Medicine, 216, Article ID: 107329. [Google Scholar] [CrossRef] [PubMed]
[28] Matteson, E.L., Kelly, C., Distler, J.H.W., Hoffmann‐Vold, A., Seibold, J.R., Mittoo, S., et al. (2022) Nintedanib in Patients with Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the inbuild Trial. Arthritis & Rheumatology, 74, 1039-1047. [Google Scholar] [CrossRef] [PubMed]
[29] Noble, P.W., Albera, C., Bradford, W.Z., Costabel, U., Glassberg, M.K., Kardatzke, D., et al. (2011) Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (CAPACITY): Two Randomised Trials. The Lancet, 377, 1760-1769. [Google Scholar] [CrossRef] [PubMed]
[30] Juge, P., Hayashi, K., McDermott, G.C., Vanni, K.M.M., Kowalski, E., Qian, G., et al. (2024) Effectiveness and Tolerability of Antifibrotics in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Seminars in Arthritis and Rheumatism, 64, Article ID: 152312. [Google Scholar] [CrossRef] [PubMed]
[31] Nurmi, H.M., Purokivi, M.K., Kärkkäinen, M.S., Kettunen, H., Selander, T.A. and Kaarteenaho, R.L. (2016) Variable Course of Disease of Rheumatoid Arthritis-Associated Usual Interstitial Pneumonia Compared to Other Subtypes. BMC Pulmonary Medicine, 16, Article No. 107. [Google Scholar] [CrossRef] [PubMed]
[32] Wells, A.U., Flaherty, K.R., Brown, K.K., Inoue, Y., Devaraj, A., Richeldi, L., et al. (2020) Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases-Subgroup Analyses by Interstitial Lung Disease Diagnosis in the INBUILD Trial: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial. The Lancet Respiratory Medicine, 8, 453-460.
[33] Tsuchiya, Y., Takayanagi, N., Sugiura, H., Miyahara, Y., Tokunaga, D., Kawabata, Y., et al. (2010) Lung Diseases Directly Associated with Rheumatoid Arthritis and Their Relationship to Outcome. European Respiratory Journal, 37, 1411-1417. [Google Scholar] [CrossRef] [PubMed]
[34] Solomon, J.J., Chung, J.H., Cosgrove, G.P., Demoruelle, M.K., Fernandez-Perez, E.R., Fischer, A., et al. (2015) Predictors of Mortality in Rheumatoid Arthritis-Associated Interstitial Lung Disease. European Respiratory Journal, 47, 588-596. [Google Scholar] [CrossRef] [PubMed]
[35] Chambers, R.C. (2022) Preferential PDE4B Inhibition—A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 386, 2235-2236. [Google Scholar] [CrossRef] [PubMed]
[36] Kolb, M., Crestani, B. and Maher, T.M. (2023) Phosphodiesterase 4B Inhibition: A Potential Novel Strategy for Treating Pulmonary Fibrosis. European Respiratory Review, 32, Article ID: 220206. [Google Scholar] [CrossRef] [PubMed]
[37] Crilly, A., Robertson, S.E., Reilly, J.H., Gracie, J.A., Lai, W., Leung, B.P., et al. (2011) Phosphodiesterase 4 (PDE4) Regulation of Proinflammatory Cytokine and Chemokine Release from Rheumatoid Synovial Membrane. Annals of the Rheumatic Diseases, 70, 1130-1137. [Google Scholar] [CrossRef] [PubMed]
[38] Mirzaei, H., Sahebkar, A., Sichani, L.S., Moridikia, A., Nazari, S., Sadri Nahand, J., et al. (2017) Therapeutic Application of Multipotent Stem Cells. Journal of Cellular Physiology, 233, 2815-2823. [Google Scholar] [CrossRef] [PubMed]
[39] Sneddon, J.B., Tang, Q., Stock, P., Bluestone, J.A., Roy, S., Desai, T., et al. (2018) Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Cell Stem Cell, 22, 810-823. [Google Scholar] [CrossRef] [PubMed]
[40] Kim, M.Y., Yu, K., Kenderian, S.S., Ruella, M., Chen, S., Shin, T., et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 173, 1439-1453.e19. [Google Scholar] [CrossRef] [PubMed]
[41] Fujita, Y. (2022) Extracellular Vesicles in Idiopathic Pulmonary Fibrosis: Pathogenesis and Therapeutics. Inflammation and Regeneration, 42, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
[42] Quan, Y., Wang, Z., Gong, L., Peng, X., Richard, M.A., Zhang, J., et al. (2017) Exosome miR-371b-5p Promotes Proliferation of Lung Alveolar Progenitor Type II Cells by Using PTEN to Orchestrate the PI3K/Akt Signaling. Stem Cell Research & Therapy, 8, Article No. 138. [Google Scholar] [CrossRef] [PubMed]
[43] Mathieu, M., Martin-Jaular, L., Lavieu, G. and Théry, C. (2019) Specificities of Secretion and Uptake of Exosomes and Other Extracellular Vesicles for Cell-to-Cell Communication. Nature Cell Biology, 21, 9-17. [Google Scholar] [CrossRef] [PubMed]
[44] Théry, C., Witwer, K.W., Aikawa, E., Alcaraz, M.J., Anderson, J.D., Andriantsitohaina, R., et al. (2018) Minimal Information for Studies of Extracellular Vesicles 2018 (MISEV2018): A Position Statement of the International Society for Extracellular Vesicles and Update of the MISEV2014 Guidelines. Journal of Extracellular Vesicles, 7, Article ID: 1535750.
[45] Zhu, L., Chen, Y., Chen, M. and Wang, W. (2021) Mechanism of Mir-204-5p in Exosomes Derived from Bronchoalveolar Lavage Fluid on the Progression of Pulmonary Fibrosis via Ap1s2. Annals of Translational Medicine, 9, 1068-1068. [Google Scholar] [CrossRef] [PubMed]
[46] Mansouri, N., Willis, G.R., Fernandez-Gonzalez, A., Reis, M., Nassiri, S., Mitsialis, S.A., et al. (2019) Mesenchymal Stromal Cell Exosomes Prevent and Revert Experimental Pulmonary Fibrosis through Modulation of Monocyte Phenotypes. JCI Insight, 4, e128060. [Google Scholar] [CrossRef] [PubMed]
[47] Yi, X., Wei, X., Lv, H., An, Y., Li, L., Lu, P., et al. (2019) Exosomes Derived from MicroRNA-30b-3p-Overexpressing Mesenchymal Stem Cells Protect against Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting SAA3. Experimental Cell Research, 383, Article ID: 111454. [Google Scholar] [CrossRef] [PubMed]
[48] Guiot, J., Cambier, M., Boeckx, A., Henket, M., Nivelles, O., Gester, F., et al. (2020) Macrophage-Derived Exosomes Attenuate Fibrosis in Airway Epithelial Cells through Delivery of Antifibrotic miR-142-3p. Thorax, 75, 870-881. [Google Scholar] [CrossRef] [PubMed]
[49] Martin-Medina, A., Lehmann, M., Burgy, O., Hermann, S., Baarsma, H.A., Wagner, D.E., et al. (2018) Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 198, 1527-1538. [Google Scholar] [CrossRef] [PubMed]
[50] Fujita, Y., Kadota, T., Araya, J., Ochiya, T. and Kuwano, K. (2018) Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases. Journal of Clinical Medicine, 7, Article 355. [Google Scholar] [CrossRef] [PubMed]
[51] Jeong, E., Hong, H., Lee, Y. and Kim, K. (2024) Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development. International Journal of Molecular Sciences, 25, Article 2682. [Google Scholar] [CrossRef] [PubMed]
[52] Citera, G., Mysler, E., Madariaga, H., Cardiel, M.H., Castañeda, O., Fischer, A., et al. (2020) Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients. JCR: Journal of Clinical Rheumatology, 27, e482-e490. [Google Scholar] [CrossRef] [PubMed]
[53] Herrinton, L.J., Harrold, L.R., Liu, L., Raebel, M.A., Taharka, A., Winthrop, K.L., et al. (2013) Association between Anti‐Tnf‐α Therapy and Interstitial Lung Disease. Pharmacoepidemiology and Drug Safety, 22, 394-402. [Google Scholar] [CrossRef] [PubMed]
[54] Venerito, V., Manfredi, A., Carletto, A., Gentileschi, S., Atzeni, F., Guiducci, S., et al. (2023) Evolution of Rheumatoid-Arthritis-Associated Interstitial Lung Disease in Patients Treated with JAK Inhibitors: A Retrospective Exploratory Study. Journal of Clinical Medicine, 12, Article 957.
[55] Ytterberg, S.R., Bhatt, D.L., Mikuls, T.R., Koch, G.G., Fleischmann, R., Rivas, J.L., et al. (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine, 386, 316-326. [Google Scholar] [CrossRef] [PubMed]
[56] Palomäki, A., Palotie, A., Koskela, J., Eklund, K.K., Pirinen, M., Ripatti, S., et al. (2021) Lifetime Risk of Rheumatoid Arthritis-Associated Interstitial Lung Disease in MUC5B Mutation Carriers. Annals of the Rheumatic Diseases, 80, 1530-1536. [Google Scholar] [CrossRef] [PubMed]
[57] Tardella, M., Di Carlo, M., Carotti, M., Ceccarelli, L., Giovagnoni, A. and Salaffi, F. (2022) A Retrospective Study of the Efficacy of JAK Inhibitors or Abatacept on Rheumatoid Arthritis-Interstitial Lung Disease. Inflammopharmacology, 30, 705-712. [Google Scholar] [CrossRef] [PubMed]
[58] Baker, M.C., Liu, Y., Lu, R., Lin, J., Melehani, J. and Robinson, W.H. (2023) Incidence of Interstitial Lung Disease in Patients with Rheumatoid Arthritis Treated with Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs. JAMA Network Open, 6, e233640. [Google Scholar] [CrossRef] [PubMed]
[59] Narváez, J., Aguilar-Coll, M., Roig-Kim, M., Maymó-Paituvi, P., Palacios-Olid, J., Nolla, J.M., et al. (2024) Janus Kinase Inhibitors in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Autoimmunity Reviews, 23, Article ID: 103636. [Google Scholar] [CrossRef] [PubMed]
[60] Komai, T., Sawada, T., Tsuchiya, H., Harada, H., Shoda, H. and Fujio, K. (2023) Resolution of Exacerbated Rheumatoid Arthritis-Associated Interstitial Lung Disease under Baricitinib Treatment. Scandinavian Journal of Rheumatology, 53, 146-148. [Google Scholar] [CrossRef] [PubMed]
[61] Fernández-Díaz, C., Atienza-Mateo, B., Castañeda, S., Melero-Gonzalez, R.B., Ortiz-SanJuan, F., Loricera, J., et al. (2021) Abatacept in Monotherapyvscombined in Interstitial Lung Disease of Rheumatoid Arthritis—Multicentre Study of 263 Caucasian Patients. Rheumatology, 61, 299-308. [Google Scholar] [CrossRef] [PubMed]
[62] Mena-Vázquez, N., Rojas-Gimenez, M., Romero-Barco, C.M., Manrique-Arija, S., Francisco, E., Aguilar-Hurtado, M.C., et al. (2021) Predictors of Progression and Mortality in Patients with Prevalent Rheumatoid Arthritis and Interstitial Lung Disease: A Prospective Cohort Study. Journal of Clinical Medicine, 10, Article 874. [Google Scholar] [CrossRef] [PubMed]
[63] Matson, S.M., Baqir, M., Moua, T., Marll, M., Kent, J., Iannazzo, N.S., et al. (2023) Treatment Outcomes for Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 163, 861-869. [Google Scholar] [CrossRef] [PubMed]
[64] Kerschbaumer, A., Sepriano, A., Bergstra, S.A., Smolen, J.S., van der Heijde, D., Caporali, R., et al. (2023) Efficacy of Synthetic and Biological Dmards: A Systematic Literature Review Informing the 2022 Update of the EULAR Recommendations for the Management of Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 82, 95-106. [Google Scholar] [CrossRef] [PubMed]
[65] Di Matteo, A., Bathon, J.M. and Emery, P. (2023) Rheumatoid Arthritis. The Lancet, 402, 2019-2033. [Google Scholar] [CrossRef] [PubMed]
[66] Fragoulis, G.E., Conway, R. and Nikiphorou, E. (2019) Methotrexate and Interstitial Lung Disease: Controversies and Questions. a Narrative Review of the Literature. Rheumatology, 58, 1900-1906. [Google Scholar] [CrossRef] [PubMed]
[67] Gupta, K. and Ravindran, V. (2025) Low-Dose Methotrexate in Rheumatology: A Reinvented Drug. Journal of the Royal College of Physicians of Edinburgh, 55, 59-68. [Google Scholar] [CrossRef] [PubMed]
[68] Conway, R., Low, C., Coughlan, R.J., O’Donnell, M.J. and Carey, J.J. (2014) Methotrexate and Lung Disease in Rheumatoid Arthritis: A Meta‐Analysis of Randomized Controlled Trials. Arthritis & Rheumatology, 66, 803-812. [Google Scholar] [CrossRef] [PubMed]
[69] Kim, K., Woo, A., Park, Y., Yong, S.H., Lee, S.H., Lee, S.H., et al. (2022) Protective Effect of Methotrexate on Lung Function and Mortality in Rheumatoid Arthritis-Related Interstitial Lung Disease: A Retrospective Cohort Study. Therapeutic Advances in Respiratory Disease, 16. [Google Scholar] [CrossRef] [PubMed]
[70] Rojas-Serrano, J., González-Velásquez, E., Mejía, M., Sánchez-Rodríguez, A. and Carrillo, G. (2012) Interstitial Lung Disease Related to Rheumatoid Arthritis: Evolution after Treatment. Reumatología Clínica, 8, 68-71. [Google Scholar] [CrossRef] [PubMed]
[71] Kurushima, S., Koga, T., Umeda, M., Iwamoto, N., Miyashita, R., Tokito, T., et al. (2024) Impact of Janus Kinase Inhibitors and Methotrexate on Interstitial Lung Disease in Rheumatoid Arthritis Patients. Frontiers in Immunology, 15, Article 1501146. [Google Scholar] [CrossRef] [PubMed]
[72] Robles-Pérez, A., Luburich, P., Bolivar, S., Dorca, J., Nolla, J.M., Molina-Molina, M., et al. (2020) A Prospective Study of Lung Disease in a Cohort of Early Rheumatoid Arthritis Patients. Scientific Reports, 10, Article No. 15640. [Google Scholar] [CrossRef] [PubMed]
[73] Albrecht, K., Strangfeld, A., Marschall, U. and Callhoff, J. (2023) Interstitial Lung Disease in Rheumatoid Arthritis: Incidence, Prevalence and Related Drug Prescriptions between 2007 and 2020. RMD Open, 9, e002777. [Google Scholar] [CrossRef] [PubMed]

为你推荐